|
|
|
| Clinical effect of Saxagliptin in the treatment of patients with type 2 diabetes mellitus complicated with metabolic syndrome and its influence on microinflammatory state |
| DENG Ying-yu LIAO Tie-jun LIN Yun-shan |
| Department of Endocrinology, Sanshui District People′ s Hospital of Foshan City, Guangdong Province, Foshan 528100, China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Saxagliptin in the treatment of patients with type 2 diabetes mellitus complicated with metabolic syndrome and its influence on microinflammatory state. Methods A total of 102 patients with type 2 diabetes complicated with metabolic syndrome admitted to our hospital from January 2017 to August 2018 were selected as research objects, and they were divide into conventional group (n=51) and experimental group (n=51) according to the random number table method. The conventional group was treated with Metformin, and the experimental group was treated with Saxagliptin on the basis of conventional group. The clinical efficacy, glycolipid metabolic indicators (fasting plasma glucose [FPG], fasting insulin [FPI], insulin resistance index [HOMA-IR], glycated hemoglobin [HbA1c], triacylglycerol [TG], total cholesterol [TC]), inflammatory factor (tumor necrosis factor-α [TNF-α],interleukin-6 [IL-6], high-sensitivity C-reactive protein [hs-CRP]) contents before and after treatment, and total incidence rate of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the experimental group (94.12%) was higher than that in the conventional group (74.51%), and the difference was statistically significant (P＜0.05). After treatment, FPG, FPI, HOMA-IR, HbA1c, TG, TC, TNF-α, IL-6, and hs-CRP in the two groups were lower than those before treatment, and the differences were statistically significant (P＜0.05). The FPG, FPI, HOMA-IR, HbA1c, TG, TC, TNF-α, IL-6, and hs-CRP in the experimental group after treatment were lower than those in the conventional group, and the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups of patients (P＞0.05). Conclusion The effect of Saxagliptin combined with Metformin in the treatment of type 2 diabetes mellitus complicated with metabolic syndrome is obvious, it can reduce the levels of glycolipid and inflammatory factors with application security,which is worth promoting.
|
|
|
|
|
|
| [1] |
姚美芳，孙雪，韩珏，等.2 型糖尿病患者合并代谢综合征增加Framingham 心血管危险评分[J].浙江大学学报（医学版），2016，45（3）：268-274.
|
| [2] |
贾珏，俞淑琴，叶菁菁，等.新诊断2 型糖尿病合并代谢综合征患者血清LDL-C/HDL-C 比值的临床研究[J].第二军医大学学报，2014，35（12）：1396-1400.
|
| [3] |
柴三葆，孙健斌，辛思旭，等.2 型糖尿病患者合并代谢综合征不同组分血脂谱分析[J].中国动脉硬化杂志，2016，24（4）：416-418.
|
| [4] |
邱晴，都健，杨晶，等.血清性激素结合球蛋白水平对2 型糖尿病患者合并代谢综合征的影响研究[J].中国全科医学，2016，19（10）：1151-1155.
|
| [5] |
任吉霞，周黎，方煜.DPP-4 抑制剂治疗糖尿病国内研究现状[J].中国医院药学杂志，2019，39（6），651-655.
|
| [6] |
郑长余.DPP-4 抑制剂西格列汀治疗糖尿病的临床效果[J].临床医学研究与实践，2019，4（13）：53-55.
|
| [7] |
谢婧，纪立伟.老年2 型糖尿病患者使用二肽基肽酶4 抑制剂的疗效和安全性评价[J].中国糖尿病杂志，2018，26（2）：173-176.
|
| [8] |
杜婧.2 型糖尿病合并代谢综合征采用吡格列酮治疗对患者胰岛素抵抗的影响观察[J].实用糖尿病杂志，2018，14（1）：24-25.
|
| [9] |
马俊花，陆建灿，王星，等.2 型糖尿病合并代谢综合征患者血清趋化素水平变化及其与白细胞介素6 的相关性[J].中国临床医学，2018，25（5）：748-752.
|
| [10] |
徐文彤.DPP-4 抑制剂类降糖药在2 型糖尿病患者中应用 的临床药学评价[J].河北医药，2017，39（22）：3496-3498.
|
| [11] |
中华医学会糖尿病分会.中国2 型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4），292-344.
|
| [12] |
陈吉，鹿斌，朱小明，等.2 型糖尿病患者代谢性炎症综合征与高敏C 反应蛋白的相关性研究[J].中国糖尿病杂志，2018，26（7）：577-580.
|
| [13] |
李玉苏，窦连军，王犇孙，等.西格列汀治疗2 型糖尿病的疗效及对胰岛β 细胞功能的影响的观察[J].贵州医药，2017，41（12）：1273-1275.
|
| [14] |
陆迪菲，马晓伟，郭晓蕙.二肽基肽酶-4 心血管系统作用的研究进展[J].中国糖尿病杂志，2016，24（11）：1049-1051.
|
| [15] |
魏书娈.维格列汀联合二甲双胍治疗2 型糖尿病合并代谢综合征[J].实用中西医结合临床，2019，19（3）：139-141.
|
| [16] |
方启金，张煜，陈梅莲，等.二肽基肽酶-4 抑制剂治疗2型糖尿病合并非酒精性脂肪肝患者的临床效果[J].中国当代医药，2019，26（14）：45-48，52.
|
|
|
|
